Learning the interaction rules of antibody-antigen binding
This project aims to enhance antibody-antigen binding prediction by generating large-scale sequence and structural data through high-throughput screening and machine learning techniques.
Projectdetails
Introduction
Antibody-antigen binding is the basis of two fundamental biotherapeutic pillars: monoclonal antibodies (1) and vaccines (2). To accelerate therapeutics discovery, we need to perform antibody (Ab) and antigen (Ag) design in silico. Specifically, we need to address a fundamental immuno-biotechnological challenge: understanding the interaction rules that predict Ab-Ag binding. Solving this challenge demands the convergence of biotechnology, computational structural biology, and machine learning (ML). My lab is one of the few worldwide to have this transdisciplinary expertise.
Research Problem
Currently, the predictive performance of Ab-Ag binding is poor, and an understanding of the underlying rules of Ab-Ag binding is mostly absent. We previously showed that both unprecedentedly large datasets (>10^5 Ab-Ag sequence pairs) and extensive structural information on the Ab-Ag binding interface (paratope, epitope) are needed to increase prediction accuracy and recover binding rules.
Targeted Breakthrough
To address the lack of large-scale Ab-Ag sequence and structural data, we will develop a method for high-throughput screening of:
-
10^3 Ab paratope-mutated variants
-
10^3 Ag epitope-mutated variants
This will generate sequence data of Ab-Ag binding pairs at an unprecedented scale (>10^6 sequence Ab-Ag pairs). Structural information of the entirety of the sequence-based Ab-Ag binding data will be generated by building and innovating on recent breakthroughs in computational structural biology.
To derive Ab-Ag interaction rules from the generated data, we will develop ML techniques for Ab-Ag binding prediction and rule recovery. We will demonstrate experimentally that we have begun to understand Ab-Ag interaction rules.
Impact
The proposed research generates the exact data necessary to recover the rules of Ab-Ag binding and provides a first groundbreaking insight into those rules, moving us closer to in silico on-demand antibody and vaccine design.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.000.000 |
Totale projectbegroting | € 2.000.000 |
Tijdlijn
Startdatum | 1-1-2024 |
Einddatum | 31-12-2028 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSITETET I OSLOpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Computational design of synthetic antibody repertoires for accelerated therapeutic discoveryCADABRE aims to design and optimize diverse human antibody repertoires with enhanced stability and developability for therapeutic discovery using advanced protein design and AI-driven screening methods. | ERC Advanced... | € 2.741.000 | 2024 | Details |
Structure and Function-based Design of Vaccine Antigens and Antiviral ImmunotherapiesThis project aims to revolutionize vaccine antigen design by utilizing nanobody screening and deep learning to extract insights from viral glycoproteins, enhancing efficacy against high-risk viruses. | ERC Starting... | € 1.499.525 | 2025 | Details |
REVisiting Antibody structures and repertoires through advances in Mass spectrometry and ProteomicsREVAMP aims to develop innovative mass spectrometry techniques to comprehensively analyze the structural and functional diversity of human antibody repertoires, enhancing our understanding of immune responses. | ERC Advanced... | € 2.500.000 | 2025 | Details |
Computer aided de novo design of nanobodiesThe project aims to automate the design of fully de novo nanobodies with nanomolar affinity using AI-driven methods, eliminating animal use and enhancing efficiency in antibody development. | ERC Proof of... | € 150.000 | 2024 | Details |
Immune Synapse Engagement as a Novel Approach for Cancer ImmunotherapyThe project aims to develop bi- and multi-specific antibodies that enhance immune cell interactions to improve the efficacy of cancer immunotherapy by targeting T-cell-dendritic cell synapses. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Computational design of synthetic antibody repertoires for accelerated therapeutic discovery
CADABRE aims to design and optimize diverse human antibody repertoires with enhanced stability and developability for therapeutic discovery using advanced protein design and AI-driven screening methods.
Structure and Function-based Design of Vaccine Antigens and Antiviral Immunotherapies
This project aims to revolutionize vaccine antigen design by utilizing nanobody screening and deep learning to extract insights from viral glycoproteins, enhancing efficacy against high-risk viruses.
REVisiting Antibody structures and repertoires through advances in Mass spectrometry and Proteomics
REVAMP aims to develop innovative mass spectrometry techniques to comprehensively analyze the structural and functional diversity of human antibody repertoires, enhancing our understanding of immune responses.
Computer aided de novo design of nanobodies
The project aims to automate the design of fully de novo nanobodies with nanomolar affinity using AI-driven methods, eliminating animal use and enhancing efficiency in antibody development.
Immune Synapse Engagement as a Novel Approach for Cancer Immunotherapy
The project aims to develop bi- and multi-specific antibodies that enhance immune cell interactions to improve the efficacy of cancer immunotherapy by targeting T-cell-dendritic cell synapses.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Accelerated Discovery Nanobody PlatformThe ALADDIN project aims to revolutionize therapeutic antibody discovery for cancer by integrating nanobody technology, AI tools, and innovative models to enhance efficiency and reduce reliance on animal testing. | EIC Pathfinder | € 3.315.441 | 2024 | Details |
Haalbaarheid van het Formula Y-platform voor versnelde antilichaam ontwikkelingHet project richt zich op het versnellen van de ontwikkeling van nieuwe antilichaamtherapieën door generatieve machine-learning algoritmes te gebruiken voor het ontwerpen van specifieke antilichamen. | Mkb-innovati... | € 20.000 | 2023 | Details |
Precision control of glycosylation to open a new era of therapeutic antibodiesGlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments. | EIC Transition | € 2.499.540 | 2025 | Details |
From A to BCR: B-Cell Receptor Repertoire Profiling for Antibody DevelopmentDit project ontwikkelt een geïntegreerde B-cel repertoire sequentiëringstechnologie om sneller en beter antilichamen te identificeren voor nieuwe geneesmiddelen en therapieën tegen kanker. | Mkb-innovati... | € 153.020 | 2020 | Details |
Accelerated Discovery Nanobody Platform
The ALADDIN project aims to revolutionize therapeutic antibody discovery for cancer by integrating nanobody technology, AI tools, and innovative models to enhance efficiency and reduce reliance on animal testing.
Haalbaarheid van het Formula Y-platform voor versnelde antilichaam ontwikkeling
Het project richt zich op het versnellen van de ontwikkeling van nieuwe antilichaamtherapieën door generatieve machine-learning algoritmes te gebruiken voor het ontwerpen van specifieke antilichamen.
Precision control of glycosylation to open a new era of therapeutic antibodies
GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.
From A to BCR: B-Cell Receptor Repertoire Profiling for Antibody Development
Dit project ontwikkelt een geïntegreerde B-cel repertoire sequentiëringstechnologie om sneller en beter antilichamen te identificeren voor nieuwe geneesmiddelen en therapieën tegen kanker.